Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Mayo Clinic in Arizona · Novo Nordisk (Denmark) · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
458
total citations
- FWCI
- 93.23
- Percentile
- 100%
- References
- 34
Citations per year
Authors
11Topics & keywords
Topics
Keywords
- Steatohepatitis
- Semaglutide
- Placebo
- Cirrhosis
- Medicine
- Internal medicine
- Steatosis
- Fatty liver
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- FFFalk Foundation
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- GSGilead Sciences
- APAlnylam Pharmaceuticals
- CCelgene
- RPRegeneron Pharmaceuticals
- APArrowhead Pharmaceuticals
- BBioCryst
- IPIntercept Pharmaceuticals
- NBNGM Biopharmaceuticals
- NINational Institute for Health and Care Research
- UOUniversity of Birmingham
- NNNovo Nordisk
- NNorgine
- GGenentech
- AAllergan
- LOLoxo Oncology
- BBBirmingham Biomedical Research Centre
- NINational Institute on Alcohol Abuse and AlcoholismAward: U01AA029019
- NHNational Heart, Lung, and Blood InstituteAwards: P30DK120515, U01AA029019, P01HL147835
- NINational Institute of Diabetes and Digestive and Kidney DiseasesAwards: R01DK121378, P30DK120515, U01DK061734, U01DK130190, R01DK106419, R01DK124318
- NCNational Center for Advancing Translational SciencesAwards: U01DK061734, U01DK130190, P30DK120515, R01DK121378, 5UL1TR001442, R01DK124318, R01DK106419
- JPJanssen Pharmaceuticals